Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INVITAE CORPORATION

(NVTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Raymond James Adjusts Price Target on Invitae to $36 From $38, Maintains Outperform Rating

11/09/2021 | 11:51am EST


ę MT Newswires 2021
All news about INVITAE CORPORATION
01/11INVITAE : Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume o..
PU
01/10Invitae Reports Jump in Revenue, Billable Volume for 2021
MT
01/10Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume ..
PR
01/10Invitae Corporation Reports Unaudited Revenue Results for the Year 2021
CI
01/05Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
PR
2021INVITAE CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2021Invitae to Seek Acquisition
CI
2021Raymond James Adjusts Price Target on Invitae to $36 From $38, Maintains Outperform Rat..
MT
2021Healthcare Stocks Inching Lower in Premarket Tuesday
MT
2021Wells Fargo Adjusts Invitae's Price Target to $25 From $35, Keeps Equal-Weight Rating
MT
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Financials (USD)
Sales 2021 460 M - -
Net income 2021 -472 M - -
Net Debt 2021 694 M - -
P/E ratio 2021 -5,38x
Yield 2021 -
Capitalization 2 658 M 2 658 M -
EV / Sales 2021 7,29x
EV / Sales 2022 5,48x
Nbr of Employees 2 900
Free-Float 97,4%
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | NVTA | US46185L1035 | MarketScreener
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 11,74 $
Average target price 32,49 $
Spread / Average Target 177%
EPS Revisions
Managers and Directors
Sean Emerson George Chairman, President & Chief Executive Officer
Roxi Wen Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric Olivares Chief Science Officer
Layton Wedgeworth Chief Technology Officer
Sector and Competitors